熱門資訊> 正文
Sanuwave Health预计第三季度收入在1140万美元至1160万美元之间
2025-10-07 04:10
- Sanuwave Health (NASDAQ:SNWV) announced on Monday that its revenues for the third quarter of 2025 are expected to be in the range of $11.4 to $11.6 million versus consensus of $12.37 million, an increase of 22% to 24% over Q3 2024. However, the revenue is below the $12-$12.7 million range of guidance given in the company’s Q2 2025 earnings release.
- “Q3 turned out to be a more challenging quarter than we expected,” said CEO Morgan Frank. “The wound care space has had quite a lot of uncertainty around the proposed reimbursement changes for certain treatment modalities, particularly skin substitutes/grafts. This uncertainty seems to have frozen the market a bit, particularly early in the quarter. Purchase decisions were delayed and patient counts reduced as providers seemed to take a ‘wait and see’ approach to potential changes. This made for a difficult environment. All in all, I think the team did well to achieve 12-14% sequential growth during this period and 22-24% vs the ‘pig through a python’ quarter last year.
- "Despite the headwinds, we sold a record number of systems in the quarter. That said, we fell short of our target and of our guidance (the first time this has happened in my tenure as CEO). The quarter started slowly, and we simply could not make up the ground, despite ending on a high note with September being the highest revenue month in Sanuwave history. That said, based on the performance in Q3, we feel it prudent at this time to alter our 2025 annual revenue guidance from $48-$50 million to $44-$46 million," added Frank.
- SNWV +0.42% after hours to $40.842.
- Source: Press Release
More on SANUWAVE Health
- Sanuwave: A Long-Term Compounder In Its Early Stages
- Sanuwave refinances debt with new credit facility
- Sanuwave Health rises after $5M payment related to patent sale
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
